Approved for use through 07/31/2008.00 (ABC).

U.S. Patent and Trademark (Diffice U.S.) DEPARTMENT OF COMMERCE
Under the Paparwork Reduction Act of 1995, no persons are required to respond to a collection of information unitest of contribution availed Wild control number.

Substitute for form 1449A/PTO				Complete if Known		
		-		Application Number	10/809,637	
	RMATION			Filing Date	March 24, 2004	
STA	TEMENT BY	/ A	PPLICANT	First Named Inventor	Jun FENG	
				Group Art Unit	1624	
(use as many sheets as necessary)				Examiner Name		
Sheet	1	of	2	Attorney Docket Number	SYR-DPP-IV-5004-C2	

			U.S. PATENT D	OCUMENTS		
Examinar	Cite	Document Number	Publication Date/	Name of Palantee or Applicant of	Pages, Columns, Lines, Where Relevant	
Initials *	No.1	Number - Kind Code <sup>2</sup> (# known)	Issue Date MM-DD-YYYY	Cited Document	Passages or Relevant Floures Appear	
	AA	US1998/5798344	12-25-1998	Kuroki et al.		
	AB	US2002/0189159	11-14-2002	Medina et al.		
	AC	US2003/0089234	4-10-2003	Medina et al.		

FOREIGN PATENT DOCUMENTS							
		Foreign Patent Document			Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear		
Examiner initials*	Cite No.1	· . Country Code <sup>3</sup> - Number <sup>4</sup> - Kind Code <sup>6</sup> (# known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document		T <sup>6</sup>	
	AD	BR 699812	11-29-1950	The Distillers Company Limited			
	AE	53005180 A	01-18-1978	Sumitomo Chem		·	
	AF	EP 1138482 A1	09-26-2001	Sanofi-Synthelabo			
	AG	WO 01/98295 A2	12-20-2001	Novartis AG			
	AH	WO 02/02580 A2	01-10-2002	Novo Nordisk			
	Al	WO 03/000181 A2	01-03-2003	Merck & Co., Inc.			
	AJ	WO 03/007888 A2	01-30-2003	Adipoganix, Inc.			
	AK	WO 03/027080 A1	04-03-2003	Mitsublshi Pharma			
	AL	WO 03/037888 A1	05-08-2003	Milsubishi Pharma			
	AM	WO 03/076418 A1	09-18-2003	X-Ceptor Therapeutics, Inc.			
	AN	WO 04/082613 A2	07-29-2004	Bristol-Myars Squibb			
	AO	WO 04/085408 A1	10-07-2004	Mitsubishi Pharma			

Examiner	Date	
Clanaton		
Signature	Considered	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw fina through citation if not in conformance and not

<sup>\*</sup>EXAMINES: Risial If influence considered, whether or not clistion is in conformance with NPEP 066, unw ten strough caused in not communicated considered. Include copy of this form with next comparison to applicate.

I Applicant's unique children designation number (goldren); 2 Applicant is to place a check mark hare it English ingrugage Translation is attached. If Applicant's unique children designation number (goldren); 2 Applicant is to place a check mark hare it English ingrugage Translation is attached and the control of the control of

PTO/SB/08A (08-03)
Approved for use through 07/3/2/2006, CMB 0951-0031
U.S. Petent and Trademant Coffice; U.S. DEPARTMENT OF COMMERCE
Under the Peperwork Reduction Act of 1995, no persons are required to respond to e collection of information unless it contains e valid OMB control number.

Substitut	le for form 1449A/PTO			Complete if Known		
				Application Number	10/809,637	
INFO	DRMATION I	DIS	CLOSURE	Filing Date	March 24, 2004	
STA	TEMENT BY	A	PPLICANT	First Named Inventor	Jun FENG	
				Group Art Unit	1624	
	(use as many shee	ts as	necessary)	Examiner Name		
Sheet	2	of	2	Attorney Docket Number	SYR-DPP-IV-5004-C2	

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS							
Examiner	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, Journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher (city and/or country where published.					
	AP	DEY, PARAMITA D., et al., Regioselective [4+2] Cycloaddillon versus Nucleophilic Reactions of N-Arylamino Substituted 1,3-Daza-1,3-Butadienes with Krienes: Systhesis of Pyrimidinone and Fused Pyrimidione Derivetives. Part II. Tetrahedron, Vol. 53, No. 40, pp. 13829-13840, 1997.					
	AQ	JAKUBKIENE, VIRGINIJA, et al., (G-Methyl-2methylsulfanyl-4-oxo-3,4-dihydro-3-pyrimidinyl)acetic ecid and related compounds exhibiting anti-Inflammatory ectivity. Pharmazie 57 (2002) 9, pp. 810-813.					
	AR	JONES, TERENCE R., et et., Azaftuorenes Containing Two Bridgehead Nitrogen Aloms. Journal of the Chemical Society, Perkin Transactions 1, No. 12, December 1987, pp. 2585-2592.					
	AS	SHARMA, ARUN K., et al. Tandem sigmatropic shifts in [4 + 2] cycloaddition reactions of 1,3-diazabuta-1,3- dienes with butadienyliketene: synthesis of pyrimidinone derivesives. J. Chem. Soc., Perkin Trans. 1, 2002, 774- 784.					
	AT	Detabese Crossfire Belistein Institut Zur Foerderung Der Chmischen Wissenscheften. XP-002310120. Belistein Registry Number 638238 & Synthetic Procedures in Nucleic Acid Chemistry, Vol. 1, 1968, page 92.					
	AU	Database Crossfire Belistein Institut Zur Foerderung Der Chmischen Wissenschaften. XP-002310119. Belistein Registry Number 649497 & J. Pharm. Sci. Vol. 80, No. 7, 1991, pp. 705-706.					
	AV	Detabase CA Onine Chemical Abstracts Service, Columbus, CH, US; Troschustz, Reinhard et el., The reaction of O-functional bearginationolities with N-bianucloophile as well as estobales. XP-002311781 mittered from STN D					
	AW	Detabese Crossfire Belistein Institut Zur Foerderung Der Chmischen Wissenscheften, XP-002310121, Belistein Registry Number 7269032 & Nucleosides Nucleotides, Vol. 14, No. 3-5, 1995, pp. 653-658.					
	AX	Detabese Crossfire Belistein Institut Zur Foerderung Der Chmischen Wissenschaften. XP-002310118, Belistein Registry Number 7643828 & KHIM. Geterotsikl, Soedin., Vol. 32, No. 5, 1998, pp. 703-707.					
	AY	Databese Crossfire Bellstein Institut Zur Foerderung Der Chmischen Wissenschaften. XP-002310117. Bellstein Registry Number 8373244 & KHIM. Geferrofstid. Soedin., No. 8, 1998, pp. 1125-1129.					

Evaminer	Date	1
LAGITITIO	Date	
Signature	Considered	
Congriculturo	00110100100	

<sup>\*\*</sup>Consideration\*\*

\*\*CVAMINER\*\* (Initial if reference considered, whether or not citation is in conformance with MPEP 600. Drew line through clastion if not in conformance and not considered, include copy of this form with next communication to applicant considered, include copy of this form with next communication to applicant to applicant the conformance with the conformance and not considered to the conformance and not conformance and not considered to the conformance and not conforma ADDRESS, SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.